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Neuromyelitis optica spectrum disorders lack imaging biomarkers associated with disease course and supporting prognosis. This
complex and heterogeneous set of disorders affects many regions of the central nervous system, including the spinal cord and visual
pathway. Here, we use graph theory-based multimodal network analysis to investigate hypothesis-free mixed networks and associa-
tions between clinical disease with neuroimaging markers in 40 aquaporin-4-immunoglobulin G antibody seropositive patients (age
¼ 48.16 6 14.3 years, female:male ¼ 36:4) and 31 healthy controls (age ¼ 45.92 6 13.3 years, female:male ¼ 24:7). Magnetic res-
onance imaging measures included total brain and deep grey matter volumes, cortical thickness and spinal cord atrophy. Optical
coherence tomography measures of the retina and clinical measures comprised of clinical attack types and expanded disability sta-
tus scale were also utilized. For multimodal network analysis, all measures were introduced as nodes and tested for directed con-
nectivity from clinical attack types and disease duration to systematic imaging and clinical disability measures. Analysis of variance,
with group interactions, gave weights and significance for each nodal association (hyperedges). Connectivity matrices from 80%
and 95% F-distribution networks were analyzed and revealed the number of combined attack types and disease duration as the
most connected nodes, directly affecting changes in several regions of the central nervous system. Subsequent multivariable regres-
sion models, including interaction effects with clinical parameters, identified associations between decreased nucleus accumbens
(b ¼ 0.85, P¼ 0.021) and caudate nucleus (b ¼ 0.61, P¼ 0.011) volumes with higher combined attack type count and longer
disease duration, respectively. We also confirmed previously reported associations between spinal cord atrophy with increased
number of clinical myelitis attacks. Age was the most important factor associated with normalized brain volume, pallidum volume,
cortical thickness and the expanded disability status scale score. The identified imaging biomarker candidates warrant further in-
vestigation in larger-scale studies. Graph theory-based multimodal networks allow for connectivity and interaction analysis, where
this method may be applied in other complex heterogeneous disease investigations with different outcome measures.
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Introduction
Neuromyelitis optica spectrum disorders (NMOSD) are in-
flammatory diseases of the central nervous system defined
by a clinical spectrum of optic neuritis (ON), myelitis, and
more rarely, brainstem and cerebral attacks (Wingerchuk
et al., 2015). The majority of patients (about 70%) are
seropositive for immunoglobulin (Ig)G antibodies against
the astrocytic water channel aquaporin-4 (AQP4-IgGþ)
(Mori et al., 2018; Cook et al., 2019). Magnetic resonance
imaging (MRI) identification of T2-hyperintense brain
lesions is useful for initial differential diagnosis and during
acute attacks, but brain lesions are often non-specific for
disability or prognosis in NMOSD (Kremer et al., 2015).
Several imaging markers have been proposed for quantify-
ing direct attack-related damage, including spinal cord at-
rophy after myelitis (Chien et al., 2018b), neuro-axonal
damage in the retina assessed by optical coherence tomog-
raphy (OCT) after ON (Schmidt et al., 2017;
Oberwahrenbrock et al., 2018; Oertel et al., 2018) and
T2-hyperintense lesions in symptomatic brainstem syn-
dromes (Kim et al., 2015).
However, it is unclear if the NMOSD disease course
also leads to covert or diffuse and clinically relevant cen-
tral nervous system damage, which can be systematically
assessed by imaging biomarkers, for example, in the grey
matter (Pache et al., 2016) or the retina (Oertel et al.,
2018). Normal MRI volumetric deep grey matter (DGM)
Graphical Abstract
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measures have been reported by some (Finke et al.,
2016), and it has been difficult to attribute clinical dis-
ability in NMOSD to systematic measures (Mealy et al.,
2019). Others reported cortical grey matter atrophy (Kim
et al., 2016) or DGM affection with clinical relevance,
i.e. for cognition (Kim et al., 2017; Oertel et al., 2019).
Complex dependencies of clinical observations and cen-
tral nervous system measures can be captured using
graph theory models relying on a network of interactions
rather than individual pairwise analyses (Lambiotte et al.,
2019). Graph theory models distinct anatomical brain
regions as nodes with connections represented by edges,
which can be exploited to calculate the strength of inter-
action between multiple regions (Fleischer et al., 2017).
Graph theory-based network analysis is typically applied
in a single modality network, e.g. magnetic resonance
imaging measures. Here, we extend this approach to
evaluate multimodal connectivity (Heath and Sioson,
2009b) between distinct systematic MRI, OCT and clinic-
al measures to identify imaging correlates of disease activ-
ity in AQP4-IgGþ NMOSD patients.
Materials and methods
Participants
Cross-sectional data from 65 participants from an on-
going observational study at the Experimental and
Clinical Research Center and the NeuroCure Clinical
Research Center, Charité-Universitätsmedizin Berlin, were
screened for inclusion in this retrospective study.
Inclusion criteria were a minimum age of 18 years, a
diagnosis of NMOSD according to the 2015
International Consensus Diagnostic Criteria (Wingerchuk
et al., 2015) with seropositivity for AQP4-IgG in a cell-
based assay (Euroimmune, Lübeck, Germany) at any time
during the course of the disease, and availability of MRI,
OCT images and clinical data. No restrictions were made
as to type of attack preventing therapy. Ophthalmologic
comorbidities (e.g. glaucoma, myopia> 5dpt) were
excluded in OCT analysis only. We included data from
40 patients with NMOSD and 31 age- and sex-matched
healthy controls (HC) from our research database
(Table 1). Disease duration was calculated from the first
clinical symptom to the date of the MRI examination.
Clinical assessments consisted of the expanded disability
status scale (EDSS), number of ON attacks, myelitis
attacks, other NMOSD-related clinical attacks (i.e. area
postrema or brainstem syndrome) and combined attacks
(i.e. simultaneous myelitis and ON or myelitis and brain-
stem syndrome). The combined attacks were counted also
as separate types of attacks, for example, a patient with
a simultaneous myelitis and brainstem attack would have
a count of one myelitis and one other attack; however,
the total number of attacks would remain as one for that
patient. The study was approved by the ethics committee
at the Charité-Universitätsmedizin Berlin, Germany (EA1/
131/09, EA1/163/12 and EA1/077/11) and was conducted
in accordance to the Declaration of Helsinki in its current
Table 1 Participant demographics
HC AQP4-IgG1 NMOSD Test
statistics
Number of subjects [n] (total ¼ 71) 31 40 NA
Age [years] (mean 6 SD) 45.92 6 13.3 48.16 6 14.3 v2 ¼ 0.7164
P ¼ 0.3973
Female:male [n] (%female) 24:7 (77%) 36:4 (92%) v2 ¼ 1.2597
P ¼ 0.2617
Disease duration [years] [mean (range)] NA 4.6 (0.47–28.06) NA





EDSS [median (range)] NA 4 (0–6.5) NA







Clinical demographics of study cohort, where attack preventing therapy counts for all patients were included prior to the MRI date.
AQP4-IgGþ NMOSD ¼ aquaporin-4 immunoglobulin-G seropositive neuromyelitis optica spectrum disorders; AZA ¼ azathioprine; BLM ¼ belimumab; EDSS ¼ expanded disability
status scale; GALA ¼ glatiramer acetate; HC ¼ healthy control; MMF ¼ mycophenolate mofetil; MTX ¼ methotrexate; N ¼ none/unknown; ON ¼ optic neuritis; RIX ¼ rituximab.
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applicable version. All participants provided written
informed consent.
Magnetic resonance imaging
All MRI scans were performed on a 3-T Siemens
MAGNETOM Trio Tim (Erlangen, Germany) scanner at
the Berlin Center for Advanced Neuroimaging. The MRI
protocol for this study included: (i) a T1-weighted 3D
magnetization-prepared rapid gradient echo brain MRI
(1 1 1 mm resolution, repetition time (TR)¼ 1900
ms, echo time (TE)¼ 3.03 ms), including the upper cer-
vical cord; and (ii) a T2-weighted 3D fluid-attenuated in-
version recovery brain MRI (1 1 1 mm resolution,
TR¼ 6000 ms, TE¼ 388 ms). All mean upper cervical
cord area (MUCCA) measurements were performed at
the C2/C3 intervertebral space level using JIM7.0
(Xinapse Systems Ltd, UK) software as described in a
previous publication (Chien et al., 2018a). Brain lesion
segmentation was performed using the automated lesion
segmentation toolbox on fluid-attenuated inversion recov-
ery images (Schmidt et al., 2012) and manually corrected
by experienced radiology technicians at our centre.
Normalized brain volume (NBV), DGM and brainstem
volumes and cortical thickness were obtained from le-
sion-filled magnetization-prepared rapid gradient echo
scans using FSL SIENAX (Smith et al., 2002), FSL FIRST
(Patenaude et al., 2011) and the CAT12 toolbox
(Dahnke et al., 2013) for MATLAB SPM12. NBV and
the total volume of DGM and brainstem structures were
normalized by multiplication with the V-Scaling factor,
an approximation of head-size given by FSL SIENAX.
Optical coherence tomography
Retinal examinations were performed using a Heidelberg
Engineering Spectralis SD-OCT (Heidelberg Engineering,
Heidelberg, Germany) with automatic real-time (ART)
function. Scan quality was checked using the OSCAR-IB
Criteria (Schippling et al., 2015) with the Advised
Protocol for OCT Study Terminology and Elements
APOSTEL recommendations (Cruz-Herranz et al., 2016).
3.4 mm ring scans around the optic nerve head were used
to measure the peripapillary retinal nerve fibre layer (12,
1536 A-scans 16automated real time tracking
(ART) 100). The ganglion cell inner plexiform (GCIP)
layer volume was measured using a 6 mm diameter cylin-
der around the fovea from macular volume scans (25 
30, 61 vertical B-scans, 768 A-scans per B-scan,
ART¼ 15). Layer segmentation was performed using Eye
Explorer 1.9.10.0, viewing module 6.3.4.0 (Heidelberg
Engineering, Heidelberg, Germany).
Multimodal network analysis
All systematic MRI, OCT and clinical measures were con-
sidered nodes in a network to test for strength of connec-
tion between the number of clinical attacks and disease
duration with EDSS, brain, spinal cord and retinal meas-
ures. Directed correlational analyses between clinical attack
counts and disease duration with all other nodes were per-
formed using ANOVA with Type III sum of squares anal-
yses, adjusted for group, thus accounting for only diseased
associations of imaging measures with clinical measures.
This type of multimodal network approach was proposed
by Heath and Siosan (Heath and Sioson, 2009a, b), where
multiple networks can be combined with interactions to
represent complex biological processes. We calculated the
union of three different networks (MRI measures, OCT
measures and clinical measures) to give a subnetwork with
‘hyperedges’ derived from the weights calculated from the
directed ANOVA F-statistics (Fig. 1A). A threshold F-stat-
istic value of 1.65 or greater was used (giving a probabil-
ity of 80% observed difference with a numerator degree
of freedom of 2 and denominator degree of freedom of
60) to define hyperedges between nodes in the network.
Significant network associations (95% F-distribution) were
then investigated by further thresholding the P-value from
each ANOVA to be <0.05. Connectivity matrices for each
network were constructed using the node pairs with F-sta-
tistics and P-values within the thresholds set for 80% and
95% probability. Both networks based on an 80% F-dis-
tribution and 95% F-distribution were evaluated for con-
nectivity, which depended on the sum of the degree,
output weight, closeness to nodes, and betweenness of
nodes, as well as the distance between nodes (Rubinov
and Sporns, 2010). These particular graph theory measures
were chosen since we employed a multimodal network
analysis, different than simple conventional directed net-
work analysis, thus we endeavoured to evaluate the com-
ponent measures which can lead to analysis of centrality,
network motifs and network comparison. Shortest distan-
ces between nodes are dependent on and calculated using
the edge list with corresponding weights (Opsahl et al.,
2010), which are related to betweenness in the nodes.
Thus, the higher the sum value for connectivity, the more
connected the node is with others in the network, suggest-
ing stronger directed associations of that node with clinical
measures. The two nodes showing the highest sum value
for connectivity were deemed as the most connected nodes
in these multimodal networks. Shortest distances were ana-
lysed in a matrix format to visualize the closeness of each
type of attack to each imaging and clinical measure. This
enabled a straightforward and interpretable post hoc ana-
lysis with covariates based on these matrices.
Statistical analysis
Proportional group differences of patient demographics in
age and sex were calculated using a Chi-squared test.
Group differences between NMOSD and HC for all MRI
and OCT measures were tested using a Mann–Whitney
U-test, without correction for multiple testing. Network
connections of MRI, OCT and EDSS measures within a
95% F-distribution that showed close distances (shortest
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weighted path length) with attack types and disease dur-
ation in the multimodal network analysis were further
investigated for effect sizes and changes in the brain, spi-
nal cord and retina of AQP4-IgGþ NMOSD patients,
using multivariable linear modelling corrected for by age.
Sex was not corrected for, due to the low number of
males in the cohort (4 out of 40). For connections with
multiple close distances with attack types and/or disease
duration, the attack types and/or disease duration were
used as interacting covariates. Leave-one-out-cross-valid-
ation was used to evaluate prediction error of multivari-
able linear models, where low overall mean squared error
(mean squared error < 20% of mean) over several fold
tests would indicate low prediction error. All statistical
analyses and plots were produced using R version 3.4.0.
Statistical significance in all tests was set to a P-value <
0.05, reflecting true test statistics (confidence intervals)
and correlation coefficients (effect sizes).
Data availability
All data from this study can be shared at the request of
other investigators for purposes of replicating procedures
and results.
Results
Group differences in magnetic
resonance imaging and optical
coherence tomography measures
Participant clinical demographics are given in Table 1.
Patient imaging measures were lower than HC (in order
of decreasing effect size) for MUCCA, GCIP, pallidum
volume, NBV and caudate nucleus volume in Mann–
Whitney U group comparisons (Table 2), but higher than
HC for T2-brain lesion count and volume. This is in line
with an earlier study using in part, overlapping data
from the same cohort study (HC: n¼ 12, NMOSD:
n¼ 32), showing none or minimal volumetric changes in
the DGM (Finke et al., 2016).
Multimodal network analysis with
80% probability of observed
correlation
We performed a multimodal network analysis with an
80% probability (F-distribution) threshold to minimize
false negatives. Analysis of nodal correlations within this
network revealed that all MRI, OCT and clinical meas-
ures were associated with different attack types and dis-
ease duration in AQP4-IgGþ NMOSD (Fig. 1B).
The number of combined attacks and disease duration
was shown to be the most connected nodes to NMOSD
MRI, OCT and clinical disability (EDSS) nodes. This was
calculated using the sum of the degree (number of con-
nections), output (directed weights of hyperedges between
nodes), closeness (strength of connections) and
Figure 1 Application of graph theory-based multimodal
network analysis on AQP4-IgG1 NMOSD MRI, OCTand
clinical data. (A) Representation of the nodes in the multimodal
network analysis employed in this study, where clinical attacks and
disease duration were investigated for their effects on retinal
measures, cortical thickness, DGM volumes, MUCCA, brain lesions
and EDSS; (B) Multimodal network analysis of 80% probability F-
distribution in AQP4-IgGþ NMOSD patient MRI, OCTand clinical
measures, where width of arrows indicate F-statistic value (wider ¼
higher value); (C) Multimodal network analysis of 95% probability F-
distribution in AQP4-IgGþ NMOSD patient MRI, OCTand clinical
measures, where width of arrows indicate F-statistic value (wider ¼
higher value). BLC ¼ brain lesion count; BLV ¼ brain lesion volume;
EDSS¼ expanded disability status scale; GCIP¼ ganglion cell inner
plexiform; INL ¼ inner nuclear layer; MUCCA ¼ mean upper
cervical cord area; NBV¼ normalized brain volume; ON ¼ optic
neuritis; pRNFL ¼ peripapillary retinal nerve fibre layer.
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betweenness (strength of interaction between two nodes)
shown in Table 3.
Multimodal network analysis with
95% probability of observed
correlation
Next, we increased the probability threshold to 95% to
limit false positives. When looking at significant
connections between attacks and disease duration with
the other MRI, OCT and clinical nodes, we found that
the number of combined attacks and disease duration
remained the most connected to changes in other meas-
ures, shown in Table 4. Meanwhile, disease-related
attacks were not found to be linked to brain lesion
counts or volume, nor thalamic or hippocampal volumes.
The number of other attacks (area postrema or brainstem
syndrome) also did not show a significant influence on
Table 3 Network analysis measures with an 80% probability of observed correlation
Node Degree Output Closeness Betweenness Sum
NBV NA NA NA NA NA
Thalamus NA NA NA NA NA
Caudate nucleus NA NA NA NA NA
Putamen NA NA NA NA NA
Pallidum NA NA NA NA NA
Hippocampus NA NA NA NA NA
Amygdala NA NA NA NA NA
Nucleus accumbens NA NA NA NA NA
Brainstem NA NA NA NA NA
Cortical thickness NA NA NA NA NA
Brain lesion number NA NA NA NA NA
Brain lesion volume NA NA NA NA NA
MUCCA NA NA NA NA NA
pRNFL NA NA NA NA NA
GCIP NA NA NA NA NA
INL NA NA NA NA NA
EDSS NA NA NA NA NA
No. of ON 10 37.639 7.996 0 55.635
No. of myelitis 8 39.863 8.468 0 56.331
No. of other attacks 4 9.118 1.937 0 15.055
No. of combined attacks 7 45.390 9.642 0 62.032
No. of total attacks 5 17.284 3.672 0 25.955
Disease duration 8 48.417 10.285 0 66.702
Directed multimodal network analysis from types of attacks and disease duration to MRI, OCTand EDSS scores. Bolded sums indicate the most connected nodes in the network.
EDSS ¼ expanded disability status scale; GCIP ¼ ganglion cell inner plexiform; INL ¼ inner nuclear layer; MUCCA ¼ mean upper cervical cord area; NBV ¼ normalized brain vol-
ume; ON ¼ optic neuritis; pRNFL ¼ peripapillary retinal nerve fibre layer.
Table 2 Group comparison of MRI and OCT measures
HC AQP4-IgG1 NMOSD Test statistics
NBV [mL] (mean 6 SD) 1542.5 6 79.4 1500.5 6 88.5 W 5 441, P 5 0.038
Thalamus [mL] (mean 6 SD) 20.8 6 1.76 20.5 6 1.82 W ¼ 604, P ¼ 0.858
Caudate nucleus [mL] (mean 6 SD) 9.46 6 1.12 8.96 6 1.05 W5 446, P 5 0.0439
Putamen [mL] (mean 6 SD) 13.0 6 1.33 12.6 6 1.53 W ¼ 498, P ¼ 0.160
Pallidum [mL] (mean 6 SD) 4.82 6 0.35 4.57 6 0.46 W 5 420, P 5 0.020
Hippocampus [mL] (mean 6 SD) 10.3 6 1.18 10.3 6 1.23 W ¼ 616, P ¼ 0.969
Amygdala [mL] (mean 6 SD) 3.66 6 0.52 3.86 6 0.58 W ¼ 745, P ¼ 0.150
Nucleus accumbens [mL] (mean 6 SD) 1.21 6 0.22 1.11 6 0.25 W ¼ 482, P ¼ 0.111
Brainstem [mL] (mean 6 SD) 29.7 6 2.41 29.9 6 2.51 W ¼ 653, P ¼ 0.708
Cortical thickness [mm2] (mean 6 SD) 2.68 6 0.09 2.71 6 0.15 W ¼ 703, P ¼ 0.341
T2 brain lesion count [n] [(median (range)] 3 (0–62) 13.5 (0–139) W 5 890, P 5 2.84e24
T2 brain lesion volume [mL] (mean 6 SD) 0.33 6 0.57 2.86 6 7.13 W 5 975, P 5 3.40e26
MUCCA [mm2] (mean 6 SD) 75.3 6 7.67 69.2 6 7.61 W 5 319, P 5 3.70e24
pRNFL [lm] (mean 6 SD) 95.0 6 9.70 82.6 6 24.1 W ¼ 276, P ¼ 0.130
GCIP [mm3] (mean 6 SD) 1.90 6 0.14 1.68 6 0.33 W 5 201, P 5 8.14e23
INL [mm3] (mean 6 SD) 0.94 6 0.06 0.95 6 0.08 W ¼ 343, P ¼ 0.908
Group comparisons of imaging measures from MRI and OCT, without adjustments or multiple testing correction. Bolded test statistics indicate statistical significance.
AQP4-IgGþ NMOSD ¼ aquaporin-4-immunoglobulin-G seropositive neuromyelitis optica spectrum disorders; GCIP ¼ ganglion cell inner plexiform; HC ¼ healthy controls; INL ¼
inner nuclear layer; MUCCA ¼ mean upper cervical cord area; NBV ¼ normalized brain volume; pRNFL ¼ peripapillary retinal nerve fibre layer.
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MRI, OCT or clinical disability measures in this cohort.
Nodes that were removed from the network due to non-
statistical significance were the inner nuclear layer, hippo-
campus, thalamus, putamen, amygdala, brainstem, brain
lesion count and volume and the number of other attacks
(Fig. 1C).
Multivariable linear analysis
We then used weighted path distances to select the closest
connections between imaging and clinical markers
(Fig. 2A and B). All connections in the 95% probability
network with a path length <2 were tested in multivari-
able linear regression models, corrected for by age, to de-
rive effect sizes of the associations. Path lengths <2 in a
binary shortest distance calculation indicate a direct con-
nection. While for instance, if two nodes are not con-
nected, but share a connection with another node, the
shortest distance (path length) between these two nodes
would be two (Opsahl et al., 2010). Thus, we specifically
chose directly connected nodes for further investigation.
Here, NBV, pallidum volume, cortical thickness and
EDSS score were only significantly associated with patient
age, but not with any clinical measures (Table 5).
Meanwhile, the number of combined attacks (i.e. simul-
taneous myelitis and ON or myelitis and brainstem syn-
drome) was significantly associated with a decrease in
the nucleus accumbens volume (b¼0.85, P¼ 0.021,
Fig. 3A). The number of myelitis attacks was associated
with decreased MUCCA (b¼4.1, P¼ 0.023), while the
number of other attacks and total number of attacks did
not affect any other node, independently. Finally, disease
duration was associated with a decrease in caudate nu-
cleus volume (b¼0.61, P¼ 0.011, Fig. 3B). Using
leave-one-out-cross-validation (Sammut and Webb, 2010),
it was found over 6-folds that there were prediction
errors of 0.0465 (mean square error ¼ 4.2% of the
mean) and 1.37 (mean squared error ¼ 15.3% of the
mean) for the nucleus accumbens and caudate nucleus
multivariable linear models, respectively. Attack type
count distributions for this patient cohort are shown in
Fig. 3C.
Discussion
Our study identified the following imaging biomarker
candidates in AQP4-IgGþ NMOSD patients, where dam-
age seemed to occur indirectly from the attack site:
a. decreases in the nucleus accumbens volume is associated
with increased number of combined attacks, and
b. decreases in the caudate nucleus volume associates with
increased disease duration.
Regarding attack-site related damage, our study con-
firmed previously reported associations of myelitis and
MUCCA (Chien et al., 2018b) in a 95% probability net-
work, as well as ON and GCIP and peripapillary retinal
nerve fibre layer (Oertel et al., 2017) when looking
broader in the 80% probability network. Age was the
Table 4 Network analysis measures with a 95% probability of observed correlation
Node Degree Output Closeness Betweenness Sum
NBV NA NA NA NA NA
Thalamus NA NA NA NA NA
Caudate nucleus NA NA NA NA NA
Putamen NA NA NA NA NA
Pallidum NA NA NA NA NA
Hippocampus NA NA NA NA NA
Amygdala NA NA NA NA NA
Nucleus accumbens NA NA NA NA NA
Brainstem NA NA NA NA NA
Cortical thickness NA NA NA NA NA
Brain lesion count NA NA NA NA NA
Brain lesion volume NA NA NA NA NA
MUCCA NA NA NA NA NA
pRNFL NA NA NA NA NA
GCIP NA NA NA NA NA
INL NA NA NA NA NA
EDSS NA NA NA NA NA
No. of ON 1 13.217 1.628 0 15.845
No. of myelitis attacks 2 23.933 2.948 0 28.881
No. of other attacks 0 0 0 0 0
No. of combined attacks 5 39.634 4.882 0 49.516
No. of total attacks 2 9.023 1.111 0 12.134
Disease duration 6 44.089 5.431 0 55.520
Directed multimodal network analysis from types of attacks and disease duration to MRI, OCTand EDSS scores. Bolded sums indicate the most connected nodes in the network.
EDSS ¼ expanded disability status scale; GCIP ¼ ganglion cell inner plexiform; INL ¼ inner nuclear layer; MUCCA ¼ mean upper cervical cord area; NBV ¼ normalized brain vol-
ume; ON ¼ optic neuritis; pRNFL ¼ peripapillary retinal nerve fibre layer.
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most important factor in measures of the NBV, pallidum
volume, cortical thickness and EDSS score.
The most intriguing finding of our study is the poten-
tial evidence of neurodegeneration in non-attack localized
regions in NMOSD, the nucleus accumbens and the
caudate nucleus. Previous studies found possible covert
damage in the optic radiation and retina, but no occult
damage in lesion-free brain regions (Pache et al., 2016;
Oertel et al., 2017; Pasquier et al., 2019). Interestingly,
an earlier study looked at markers for cognitive impair-
ment in NMOSD patients and found that nucleus accum-
bens volume was associated with overall cognition and
cognitive impairment in these patients. Moreover, cogni-
tively impaired patients with NMOSD showed atrophy in
the caudate nucleus (Kim et al., 2017). Although we did
not specifically consider cognitive impairment in this
study, Kim et al.’s findings alongside ours, serve as inde-
pendent verification that the nucleus accumbens and
caudate nucleus are affected in AQP4-IgGþ NMOSD
patients. The nucleus accumbens has been implicated in
neuropathic pain and neuropsychiatric conditions and is
suggested to be modulated in an aquaporin-4-dependent
manner (Wu et al., 2018). Previously, we also found
moderate to severely depressed NMOSD patients are
more susceptible to insufficiently mediated neuropathic
pain and fatigue (Chavarro et al., 2016; Asseyer et al.,
2018). Together, these data suggest that nucleus accum-
bens and caudate nucleus affection in NMOSD may be a
true positive finding, warranting further confirmation, al-
though the underlying mechanism remains elusive. Due to
these interesting findings, we are encouraged to investi-
gate the potential changes in cognitive, executive and
mood functions of NMOSD patients and their associa-
tions with DGM volumes calculated from MRI scans.
The main suggested mechanism of damage by aqua-
porin-4 antibodies in NMOSD is immune-mediated
Figure 2 Nodal connections and their distances calculated from multimodal network analysis. (A) Distances calculated from the
80% probability multimodal network analysis of each attack node (x-axis) and their connection to different MRI, OCTand clinical disability
measures (y-axis); (B) Distances calculated from the 95% probability multimodal network analysis of each node connection to different MRI,
OCTand clinical disability measures. Magenta squares ¼ <1 unit away, grey squares ¼ >1 unit away. Distances (shortest path lengths) have no
measurement units, as the connection lengths are based on the weight of each hyperedge (F-statistic value). EDSS ¼ expanded disability status
scale; GCIP ¼ ganglion cell inner plexiform; INL ¼ inner nuclear layer; MUCCA ¼ mean upper cervical cord area; ON ¼ optic neuritis; pRNFL
¼ peripapillary retinal nerve fibre layer.
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Figure 3. Associations and distributions of disease-related attacks. Multivariable linear regression models of (A) the nucleus accumbens
volume versus the number of combined attacks and (B) the caudate nucleus volume versus the disease duration in AQP4-IgGþ NMOSD patients,
corrected for age. (C) Distribution of attack type counts in this cohort. Abbreviations: ON¼optic neuritis.
10 | BRAIN COMMUNICATIONS 2019: Page 10 of 13 C. Chien et al.
attacks against astrocytes, subsequent metabolic break-
down at the attack site and resulting axonal transsection
throughout structural pathways, such as the anterior vis-
ual pathway (Kuchling et al., 2018). In line with attack-
related damage, associations of decreased MUCCA with
an increased number of clinical myelitis attacks were pre-
viously found (Chien et al., 2018b). Regarding retinal
measures, previous studies have established peripapillary
retinal nerve fibre layer and GCIP as potential measures
of NMOSD attack-related damage (Oertel et al., 2018).
Our results are in accordance with previous findings,
thus strengthening the likelihood that this multimodal
network analysis technique is yielding true positive
results.
Age is a well-known factor in brain atrophy measures
(Opfer et al., 2018), which we also observed. In fact, age
has been found to affect the majority of grey matter atro-
phy measures typically associated with disease, e.g. in
multiple sclerosis (Barkhof et al., 2009). Our study indi-
cates that there may also be disease-related atrophy in
the pallidum, cortical thickness and NBV in larger
cohorts, when adjusted for age. Despite earlier studies
finding no group differences with HC (Finke et al., 2016;
Pasquier et al., 2019), these studies did not look at the
complex interactions of MRI or OCT measures in rela-
tion to clinical attacks and disability measures, which
multimodal network analysis allows for. Therefore, this
study serves as an exemplary showcase for directed graph
theory-based multimodal network analysis.
The cross-sectional exploratory nature and small sam-
ple size, including the low number of other attacks
(brainstem or area postrema syndrome), are important
limitations. To account for both physiological fluctuations
and noisy data, we performed the multimodal network
analysis using F-statistics calculated from an ANOVA
with Type III sum of squares, including HC and patients.
This method allows for accurate testing of main effects
and interactions, as well as accounting for between-group
and within-group variances (Kim, 2014). Inclusion of HC
data and interaction effects in the models to minimize
physiological and disease-unrelated effects is a clear
strength of our approach. This method could be applied
to studies where patients were treated with different at-
tack preventing therapies to allow for evaluation of
treatment–imaging relationships. We were not able to in-
vestigate this in our study due to the cross-sectional and
retrospective nature, as well as subgrouping the heteroge-
neous attack preventing therapies would not have led to
sufficient group sizes for any meaningful analysis. It is
thus, a limitation that we cannot fully differentiate if
there are central nervous system volume effects based
on attack preventing therapy, neurodegeneration,
astrocytopathy or inflammation. However, one may find
it feasible to use therapies as interaction effects in future
larger and longitudinal studies. We were also limited by
the low number of attacks in our patient cohort, where
very few patients had combined attacks; however, we
performed a leave-one-out-cross-validation analysis of the
multivariable linear regression models used for the nu-
cleus accumbens and caudate nucleus volumes. This val-
idation analysis gave low mean squared error values,
thus, indicating that despite a skewness towards lower at-
tack counts, the complex regression models fit quite well
and can aid in the prediction of volumetric changes based
on real-world combined attack and disease duration data.
In summary, using graph theory-based multimodal net-
work analysis, we identified two DGM imaging biomark-
er candidates in AQP4-IgGþ NMOSD. Rather than
studying the localized region of disease-related attacks,
multimodal network analysis gives insights into connectiv-
ity and interactions between multiple regions in the cen-
tral nervous system that can lead to knowledge gain of
damage as part of a complex, dynamic system. The net-
work approach provides an avenue for future investiga-
tions of potential biomarkers, or associated changes to
monitor for clinical trials to treat many neurologically
complex diseases in large and heterogeneous datasets.
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